What is the appropriate evaluation and management for a 54-year-old male with primary hyperaldosteronism presenting with heat‑induced palpitations and generalized weakness?

Immediate Evaluation and Management

This patient requires urgent assessment for hypokalemia-induced cardiac arrhythmia and muscle weakness, with immediate potassium replacement and initiation of mineralocorticoid receptor antagonist (MRA) therapy to prevent life-threatening complications.

Acute Evaluation

Immediate Laboratory Assessment

• Serum potassium level - The heat-induced palpitations and generalized weakness strongly suggest hypokalemia, a common and dangerous complication of primary hyperaldosteronism that can precipitate cardiac arrhythmias 1
• ECG - Essential to evaluate for arrhythmias (atrial fibrillation risk is 3.5-fold higher in PA) and hypokalemia-related changes (U waves, T wave flattening, QT prolongation) 1
• Renal function and electrolytes - Monitor for concurrent metabolic alkalosis and assess baseline kidney function before MRA initiation

Critical Clinical Context

Heat exposure exacerbates hypokalemia in PA patients through increased aldosterone-mediated potassium wasting via sweat and urine. The combination of palpitations and weakness indicates potentially dangerous potassium depletion requiring urgent correction 2.

Immediate Management

Potassium Replacement

• Correct hypokalemia before any further diagnostic testing - This is critical as hypokalemia can suppress aldosterone secretion and interfere with accurate aldosterone-renin ratio interpretation
• Oral potassium supplementation is preferred unless severe (<2.5 mEq/L) or symptomatic with arrhythmias, which would require IV replacement
• Target potassium >4.0 mEq/L before proceeding with treatment optimization

Initiate MRA Therapy

Spironolactone is the first-line treatment for this patient 3, 1. The 2025 Endocrine Society guideline specifically recommends spironolactone over other MRAs due to low cost and widespread availability 3.

Starting regimen:

• Begin spironolactone 25-50 mg daily (consider hypertension severity for initial dosing)
• Monitor potassium, renal function, renin, and blood pressure within 1-2 weeks
• Titrate dose upward to raise renin from baseline if blood pressure remains uncontrolled 3
• Alternative: Eplerenone at 2-3 times the spironolactone dose if anti-androgenic side effects are a concern 1

Blood Pressure Management

• May need to discontinue or reduce other antihypertensives when initiating MRA therapy 3
• The goal is to normalize blood pressure AND mitigate aldosterone excess effects on cardiovascular and renal systems 1

Subtype Evaluation (If Not Already Completed)

Since this is a 54-year-old male with established PA diagnosis, determine if he is a surgical candidate:

Indications for Adrenal Venous Sampling (AVS)

• If the patient desires and is a candidate for adrenalectomy, AVS is required to differentiate unilateral from bilateral disease 3
• Exceptions where AVS may be bypassed:
  • Age <35 years with marked PA, hypokalemia, and >1.0 cm unilateral adenoma on CT 3
  • Multiple comorbidities making him a poor surgical candidate - proceed directly to medical therapy 3
  • Patient preference for medical management

Additional Screening

Perform 1-mg overnight dexamethasone suppression test if adrenal adenoma is present 3:

• Give 1 mg dexamethasone orally at 23:00-24:00
• Measure serum cortisol at 08:00-09:00 next morning
• Cortisol >1.8 μg/dL suggests autonomous cortisol secretion requiring further evaluation
• This is important as concurrent cortisol excess increases cardiovascular risk

Follow-Up Monitoring

Monitor the following parameters to guide MRA dose titration 3:

• Potassium levels (watch for hyperkalemia with MRA therapy)
• Renal function (creatinine)
• Renin concentration or activity (titrate MRA to raise renin from baseline)
• Blood pressure response

Common Pitfalls to Avoid

1. Do not perform aldosterone-renin ratio testing during acute hypokalemia - This will yield false-negative results
2. Do not assume medical therapy alone is sufficient without subtyping - Unilateral disease may be surgically curable, offering superior cardiovascular risk reduction 1
3. Do not overlook cardiac evaluation - PA patients have significantly elevated risk of atrial fibrillation (OR 3.52), heart failure (OR 2.05), and stroke (OR 2.58) compared to essential hypertension 1
4. Monitor for hyperkalemia after MRA initiation - Especially with concurrent renal impairment

Treatment Goals

The primary objectives are to normalize blood pressure, correct hypokalemia, mitigate aldosterone-mediated organ damage, and reduce cardiovascular mortality 1. Targeted PA treatment reduces cardiovascular morbidity beyond blood pressure control alone - this patient's palpitations and weakness represent potentially preventable complications of undertreated disease 2.